Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En studie om modifierade RNA-vacciner mot influensa hos friska vuxna

9 juni 2026 uppdaterad av: Pfizer

EN STUDIE FÖR ATT UTVÄRDERA SÄKERHETEN, TOLERABILITETEN OCH IMMUNOGENICITETEN HOS MODIFIERADE RNA-vacciner mot influensa hos friska vuxna

Syftet med denna studie är att lära sig om modifierade RNA (modRNA)-vacciner för att förebygga influensa är:

  • säker; och
  • hur dessa vacciner producerar ett immunsvar hos allmänt friska vuxna. Immunsvar är hur kroppen skyddar sig mot saker som den ser som skadliga eller främmande.

RNA (även kallad ribonukleinsyra) är en av två typer av nukleinsyra som tillverkas av celler. RNA innehåller information som har kopierats från DNA (den andra typen av nukleinsyra). Celler gör flera olika former av RNA, och varje form har ett specifikt jobb i cellen. Många former av RNA har funktioner relaterade till att göra proteiner. RNA är också det genetiska materialet i vissa virus istället för DNA. RNA kan tillverkas i laboratoriet och användas i forskningsstudier. Kallas även ribonukleinsyra.

Influensa är en term som används för influensasjukdom. Det är en infektion som orsakas av ett virus som påverkar din mun, näsa och svalg.

Studien söker deltagare som:

  • är minst 18 år gamla
  • inte har fått något influensavaccin under de senaste 6 månaderna
  • är allmänt friska

Denna studie kommer att delas upp i tre delstudier: Delstudie A (SSA), Delstudie B (SSB) och Delstudie C (SSC).

Alla deltagare, oavsett delstudie, kommer att få 1 dos av något av följande vacciner som en injektion i armen:

  • 1 av modRNA-influensavaccinerna som studeras; eller
  • ett godkänt influensavaccin godkänt för användning i deras respektive åldersgrupp.

Deltagarna kommer att vara involverade i denna studie i cirka 6 månader. Under denna tid kommer deltagarna att ha minst 3 klinikbesök.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Faktisk)

1202

Fas

  • Fas 2
  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Alabama
      • Mobile, Alabama, Förenta staterna, 36608
        • AMR Clinical
    • Arizona
      • Scottsdale, Arizona, Förenta staterna, 85260
        • Headlands Research - Scottsdale
    • California
      • Anaheim, California, Förenta staterna, 92801
        • Anaheim Clinical Trials, LLC
      • Lake Forest, California, Förenta staterna, 92630
        • Orange County Research Center
      • San Diego, California, Förenta staterna, 92103
        • Artemis Institute for Clinical Research
      • Walnut Creek, California, Förenta staterna, 94598
        • Diablo Clinical Research, Inc.
    • Connecticut
      • Milford, Connecticut, Förenta staterna, 06460
        • Clinical Research Consulting
    • Florida
      • Hialeah, Florida, Förenta staterna, 33012
        • Indago Research & Health Center, Inc
      • Hollywood, Florida, Förenta staterna, 33024
        • Research Centers of America
      • Hollywood, Florida, Förenta staterna, 33024
        • Research Centers of America ( Hollywood )
      • Miami Lakes, Florida, Förenta staterna, 33014
        • Palm Springs Community Health Center
      • Orlando, Florida, Förenta staterna, 32801
        • Clinical Neuroscience Solutions, Inc.
      • Orlando, Florida, Förenta staterna, 32819
        • Headlands Research Orlando
      • South Miami, Florida, Förenta staterna, 33143
        • Qps-Mra, Llc
    • Hawaii
      • Honolulu, Hawaii, Förenta staterna, 96814
        • East-West Medical Research Institute
    • Louisiana
      • New Orleans, Louisiana, Förenta staterna, 70119
        • Alliance for Multispecialty Research, LLC
    • Minnesota
      • Saint Paul, Minnesota, Förenta staterna, 55114
        • Prism Research LLC dba Nucleus Network
    • Missouri
      • Chesterfield, Missouri, Förenta staterna, 63005
        • Clinical Research Professionals
      • Kansas City, Missouri, Förenta staterna, 64114
        • Alliance for Multispecialty Research, LLC
    • New York
      • Rochester, New York, Förenta staterna, 14609
        • Rochester Clinical Research, LLC
    • North Carolina
      • Durham, North Carolina, Förenta staterna, 27703
        • Duke Vaccine and Trials Unit
      • Raleigh, North Carolina, Förenta staterna, 27612
        • M3 Wake Research, Inc.
    • Pennsylvania
      • Philadelphia, Pennsylvania, Förenta staterna, 19107
        • DM Clinical Research - Philadelphia
    • Texas
      • Brownsville, Texas, Förenta staterna, 78526
        • Headlands Horizons LLC
      • Mesquite, Texas, Förenta staterna, 75149
        • SMS Clinical Research
      • San Antonio, Texas, Förenta staterna, 78229
        • Clinical Trials of Texas, LLC
      • San Antonio, Texas, Förenta staterna, 78229
        • Clinical Trials of Texas, LLC dba Flourish Research
      • Tomball, Texas, Förenta staterna, 77375
        • Dynamed Clinical Research, LP d/b/a DM Clinical Research
    • Utah
      • Salt Lake City, Utah, Förenta staterna, 84109
        • J. Lewis Research, Inc. / Foothill Family Clinic
      • Salt Lake City, Utah, Förenta staterna, 84121
        • J. Lewis Research, Inc. / Foothill Family Clinic South
    • Virginia
      • Charlottesville, Virginia, Förenta staterna, 22911
        • Charlottesville Medical Research
      • Norfolk, Virginia, Förenta staterna, 23502
        • AMR Clinical

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Ja

Beskrivning

Viktiga inkluderingskriterier

Gäller alla 3 delstudier:

  • deltagare ≥18 år.
  • allmänt friska deltagare.

ENDAST delstudie C:

- mottagande av licensierad influensavaccination för influensasäsongen 2023-2024 för minst 6 månader sedan.

Viktiga uteslutningskriterier

Alla 3 delstudier:

  • diagnos av influensa (genom kliniska tester) under de senaste 6 månaderna.
  • immunförsvagade individer med känd eller misstänkt immunbrist
  • mottagande av eventuella prövnings- eller licensierade influensavacciner inom 6 månader.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: SSA: Influensa ModRNA-vaccin 2A
- Engångsdos på dag 1
Intramuskulär injektion
Experimentell: SSA: Influensa ModRNA-vaccin 3A
- Engångsdos på dag 1
Intramuskulär injektion
Experimentell: SSA: Influensa ModRNA-vaccin 4A
- Engångsdos på dag 1
Intramuskulär injektion
Experimentell: SSA: Influensa ModRNA-vaccin 5A
- Engångsdos på dag 1
Intramuskulär injektion
Aktiv komparator: SSA: QIV1
- Engångsdos på dag 1
Intramuskulär injektion
Experimentell: SSB: Influensa ModRNA-vaccin 3B
- Engångsdos på dag 1
Intramuskulär injektion
Experimentell: SSB: Influensa ModRNA-vaccin 4B
- Engångsdos på dag 1
Intramuskulär injektion
Experimentell: SSB: Influensa ModRNA-vaccin 5B
- Engångsdos på dag 1
Intramuskulär injektion
Aktiv komparator: SSB: QIV2
- Engångsdos på dag 1
Intramuskulär injektion
Aktiv komparator: SSB: QIV3
- Engångsdos på dag 1
Intramuskulär injektion
Experimentell: SSC: Influensa ModRNA Vaccine 3C
- Engångsdos på dag 1
Intramuskulär injektion
Experimentell: SSC: Influensa ModRNA Vaccine 4C
- Engångsdos på dag 1
Intramuskulär injektion
Experimentell: SSC: Influensa ModRNA Vaccine 5C
- Engångsdos på dag 1
Intramuskulär injektion
Experimentell: SSC: Influensa ModRNA Vaccine 6C
- Engångsdos på dag 1
Intramuskulär injektion
Experimentell: SSC: Influensa ModRNA Vaccine 7C
- Engångsdos på dag 1
Intramuskulär injektion
Experimentell: SSC: Influensa ModRNA Vaccine 8C
- Engångsdos på dag 1
Intramuskulär injektion
Experimentell: SSC: Influensa ModRNA Vaccine 9C
- Engångsdos på dag 1
Intramuskulär injektion
Aktiv komparator: SSC: QIV2
- Engångsdos på dag 1
Intramuskulär injektion
Aktiv komparator: SSC: QIV3
- Engångsdos på dag 1
Intramuskulär injektion

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
SSA: Percentage of Participants With Local Reactions for up to 7 Days Following Vaccination
Tidsram: From Day 1 through Day 7 after study vaccination [Vaccination on Day 1]
Local reactions included pain at the injection site, redness and swelling and were recorded by participants in the electronic dairy (e-diary) or by investigators in case report form (CRF) after vaccination. All local reactions were graded based on center for biologics evaluation and research (CBER) toxicity guidelines as Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe) and Grade 4 (potentially life-threatening). In this outcome measure, data is reported as percentage of participants with any local reaction of any grade.
From Day 1 through Day 7 after study vaccination [Vaccination on Day 1]
SSB: Percentage of Participants With Local Reactions for up to 7 Days Following Vaccination
Tidsram: From Day 1 through Day 7 after study vaccination [Vaccination on Day 1]
Local reactions included pain at the injection site, redness and swelling and were recorded by participants in the e-diary or by investigators in CRF after vaccination. All local reactions were graded based on CBER toxicity guidelines as Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe) and Grade 4 (potentially life-threatening). In this outcome measure, data is reported as percentage of participants with any local reaction of any grade.
From Day 1 through Day 7 after study vaccination [Vaccination on Day 1]
SSC: Percentage of Participants With Local Reactions for up to 7 Days Following Vaccination
Tidsram: From Day 1 through Day 7 after study vaccination [Vaccination on Day 1]
Local reactions included pain at the injection site, redness and swelling and were recorded by participants in the e-diary or by investigators in CRF after vaccination. All local reactions were graded based on CBER toxicity guidelines as Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe) and Grade 4 (potentially life-threatening). In this outcome measure, data is reported as percentage of participants with any local reaction of any grade.
From Day 1 through Day 7 after study vaccination [Vaccination on Day 1]
SSA: Percentage of Participants With Systemic Events for up to 7 Days Following Vaccination
Tidsram: From Day 1 through Day 7 after study vaccination [Vaccination on Day 1]
Systemic events (fever, vomiting, diarrhea, headache, fatigue, chills, new or worsened muscle pain and joint pain) were recorded by participants in the e-diary or by investigators in CRF after vaccination. All systemic events were graded based on CBER toxicity guidelines as Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe) and Grade 4 (potentially life-threatening). In this outcome measure, data is reported as percentage of participants with any systemic events of any grade.
From Day 1 through Day 7 after study vaccination [Vaccination on Day 1]
SSB: Percentage of Participants With Systemic Events for up to 7 Days Following Vaccination
Tidsram: From Day 1 through Day 7 after study vaccination [Vaccination on Day 1]
Systemic events (fever, vomiting, diarrhea, headache, fatigue, chills, new or worsened muscle pain and joint pain) were recorded by participants in the e-diary or by investigators in CRF after vaccination. All systemic events were graded based on CBER toxicity guidelines as Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe) and Grade 4 (potentially life-threatening). In this outcome measure, data is reported as percentage of participants with any systemic events of any grade.
From Day 1 through Day 7 after study vaccination [Vaccination on Day 1]
SSC: Percentage of Participants With Systemic Events for up to 7 Days Following Vaccination
Tidsram: From Day 1 through Day 7 after study vaccination [Vaccination on Day 1]
Systemic events (fever, vomiting, diarrhea, headache, fatigue, chills, new or worsened muscle pain and joint pain) were recorded by participants in the e-diary or by investigators in CRF after vaccination. All systemic events were graded based on CBER toxicity guidelines as Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe) and Grade 4 (potentially life-threatening). In this outcome measure, data is reported as percentage of participants with any systemic events of any grade.
From Day 1 through Day 7 after study vaccination [Vaccination on Day 1]
SSA: Percentage of Participants With Adverse Events (AEs) From Vaccination Through 4 Weeks After Vaccination
Tidsram: From study vaccination on Day 1 through 4 weeks after study vaccination
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) were included in this outcome measure.
From study vaccination on Day 1 through 4 weeks after study vaccination
SSB: Percentage of Participants With AEs From Vaccination Through 4 Weeks After Vaccination
Tidsram: From study vaccination on Day 1 through 4 weeks after study vaccination
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) were included in this outcome measure.
From study vaccination on Day 1 through 4 weeks after study vaccination
SSC: Percentage of Participants With AEs From Vaccination Through 4 Weeks After Vaccination
Tidsram: From study vaccination on Day 1 through 4 weeks after study vaccination
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (excluding local reactions and systematic events) were included in this outcome measure.
From study vaccination on Day 1 through 4 weeks after study vaccination
SSA: Percentage of Participants With SAEs From Vaccination Through 6 Months After Vaccination
Tidsram: From study vaccination on Day 1 through 6 months after study vaccination
An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, any other pre-specified criteria in protocol of the study or other important medical event judged by the investigator.
From study vaccination on Day 1 through 6 months after study vaccination
SSB: Percentage of Participants With SAEs From Vaccination Through 6 Months After Vaccination
Tidsram: From study vaccination on Day 1 through 6 months after study vaccination
An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, any other pre-specified criteria in protocol of the study or other important medical event judged by the investigator.
From study vaccination on Day 1 through 6 months after study vaccination
SSC: Percentage of Participants With SAEs From Vaccination Through 6 Months After Vaccination
Tidsram: From study vaccination on Day 1 through 6 months after study vaccination
An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, any other pre-specified criteria in protocol of the study or other important medical event judged by the investigator.
From study vaccination on Day 1 through 6 months after study vaccination
SSA: Percentage of Participants With Medically Attended Adverse Events (MAEs) From Vaccination Through 6 Months After Vaccination
Tidsram: From study vaccination on Day 1 through 6 months after study vaccination
An MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility.
From study vaccination on Day 1 through 6 months after study vaccination
SSB: Percentage of Participants With MAEs From Vaccination Through 6 Months After Vaccination
Tidsram: From study vaccination on Day 1 through 6 months after study vaccination
An MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility.
From study vaccination on Day 1 through 6 months after study vaccination
SSC: Percentage of Participants With MAEs From Vaccination Through 6 Months After Vaccination
Tidsram: From study vaccination on Day 1 through 6 months after study vaccination
An MAE was defined as a non-serious AE that resulted in an evaluation at a medical facility.
From study vaccination on Day 1 through 6 months after study vaccination
SSA: Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Vaccination Through 6 Months After Vaccination
Tidsram: From study vaccination on Day 1 through 6 months after study vaccination
An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects (e.g., asthma).
From study vaccination on Day 1 through 6 months after study vaccination
SSB: Percentage of Participants With NDCMCs From Vaccination Through 6 Months After Vaccination
Tidsram: From study vaccination on Day 1 through 6 months after study vaccination
An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects (e.g., asthma).
From study vaccination on Day 1 through 6 months after study vaccination
SSC: Percentage of Participants With NDCMCs From Vaccination Through 6 Months After Vaccination
Tidsram: From study vaccination on Day 1 through 6 months after study vaccination
An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects (e.g., asthma).
From study vaccination on Day 1 through 6 months after study vaccination

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
SSA: Geometric Mean Titers (GMTs) of Strain-Specific Hemagglutination Inhibition Assay (HAI) Titers at Baseline and 4 Weeks After Vaccination
Tidsram: Baseline (before study vaccination on Day 1), 4 weeks after study vaccination
GMTs and the corresponding 2-sided 95% confidence intervals (CIs) were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).
Baseline (before study vaccination on Day 1), 4 weeks after study vaccination
SSA: Geometric Mean Fold Rise (GMFR) of Strain-Specific HAI Titers From Before Vaccination to 4 Weeks After Vaccination
Tidsram: From before study vaccination on Day 1 up to 4 weeks after study vaccination
GMFR was defined as the geometric mean of the fold rise in the assay results from before vaccination to a specified time point after vaccination.
From before study vaccination on Day 1 up to 4 weeks after study vaccination
SSA: Percentage of Participants Achieving HAI Seroconversion for Each Strain at 4 Weeks After Vaccination
Tidsram: 4 weeks after study vaccination
Seroconversion was defined as an HAI titer <1:10 prior to vaccination and >=1:40 at the time point of interest, or an HAI titer of >=1:10 prior to vaccination with at least a 4-fold rise at the time point of interest.
4 weeks after study vaccination
SSA: Percentage of Participants With HAI Titers >=1:40 For Each Strain at Baseline and 4 Weeks After Vaccination
Tidsram: Baseline (before study vaccination on Day 1), 4 weeks after study vaccination
This measure is for percentage of participants achieving HAI titers >=1:40 for each strain.
Baseline (before study vaccination on Day 1), 4 weeks after study vaccination
SSB: GMTs of Strain-Specific HAI Titers at Baseline and 4 Weeks After Vaccination
Tidsram: Baseline (before study vaccination on Day 1), 4 weeks after study vaccination
Baseline (before study vaccination on Day 1), 4 weeks after study vaccination
SSB: GMFRs of Strain-Specific HAI Titers From Before Vaccination to 4 Weeks After Vaccination
Tidsram: From before study vaccination on Day 1 up to 4 weeks after study vaccination
From before study vaccination on Day 1 up to 4 weeks after study vaccination
SSB: Percentage of Participants Achieving HAI Seroconversion for Each Strain at 4 Weeks After Vaccination
Tidsram: 4 weeks after study vaccination
4 weeks after study vaccination
SSB: Percentage of Participants With HAI Titers >=1:40 For Each Strain at Baseline and 4 Weeks After Vaccination
Tidsram: Baseline (before study vaccination on Day 1), 4 weeks after study vaccination
This measure is for percentage of participants achieving HAI titers >=1:40 for each strain.
Baseline (before study vaccination on Day 1), 4 weeks after study vaccination

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Studierektor: Pfizer CT.gov Call Center, Pfizer

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

23 maj 2024

Primärt slutförande (Faktisk)

5 februari 2025

Avslutad studie (Faktisk)

5 februari 2025

Studieregistreringsdatum

Först inskickad

24 maj 2024

Först inskickad som uppfyllde QC-kriterierna

30 maj 2024

Första postat (Faktisk)

31 maj 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

12 juni 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

9 juni 2026

Senast verifierad

1 juni 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Pfizer kommer att ge tillgång till individuella avidentifierade deltagardata och relaterade studiedokument (t.ex. protokoll, Statistisk analysplan (SAP), Clinical Study Report (CSR)) på begäran från kvalificerade forskare, och med förbehåll för vissa kriterier, villkor och undantag. Ytterligare information om Pfizers kriterier för datadelning och process för att begära åtkomst finns på: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera